Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development

In drug development, in vivo assessment of target engagement provides confidence when testing the drug's mechanism of action and improves the likelihood of clinical success. For biologics, receptor occupancy (RO) determined from circulating cells can provide evidence of target engagement. Integrating this information with mathematical modeling can further enhance the understanding of drug‐target interactions and the biological factors that are critical to the successful modulation of the target and ultimately the disease state.

[1]  L. Sklar,et al.  Ligand/receptor internalization: a kinetic, flow cytometric analysis of the internalization of N-formyl peptides by human neutrophils. , 1983, Cytometry.

[2]  Jason M. Edmonds,et al.  Quantitative Analysis of Target Coverage and Germinal Center Response by a CXCL13 Neutralizing Antibody in a T-Dependent Mouse Immunization Model , 2013, Pharmaceutical Research.

[3]  Jan Passchier,et al.  Measuring drug-related receptor occupancy with positron emission tomography. , 2002, Methods.

[4]  Dhaval K. Shah,et al.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  D. Mager.  Target-mediated drug disposition and dynamics. , 2006, Biochemical pharmacology.

[6]  H. Wiley,et al.  Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. , 1990, The Journal of biological chemistry.

[7]  S. Piscitelli,et al.  In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti‐HIV Activity of Aplaviroc , 2008, Journal of clinical pharmacology.

[8]  Donald E. Mager,et al.  General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  P. Jacqmin,et al.  Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. , 2008, British journal of clinical pharmacology.

[10]  E. Kraynov,et al.  Receptor occupancy and blocking of STAT5 signaling by an anti‐IL‐7 receptor α antibody in cynomolgus monkeys , 2016, Cytometry. Part B, Clinical cytometry.

[11]  Peiming Ma.  Theoretical Considerations of Target-Mediated Drug Disposition Models: Simplifications and Approximations , 2011, Pharmaceutical Research.

[12]  J. Sims,et al.  On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. , 2010, Basic & clinical pharmacology & toxicology.

[13]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[14]  Tove Tuntland,et al.  Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research , 2014, Front. Pharmacol..

[15]  K. Kairemo,et al.  Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody. , 2009, Current pharmaceutical design.

[16]  J. Gibbs,et al.  A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design , 2014, mAbs.

[17]  Paolo Vicini,et al.  Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies , 2013, The AAPS Journal.

[18]  Aman P. Singh,et al.  Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition , 2014, The AAPS Journal.

[19]  E. Kraynov,et al.  A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition , 2012, Journal of Pharmacology and Experimental Therapeutics.

[20]  Anson K. Abraham,et al.  Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  J. Masferrer,et al.  pSTAT3: a target biomarker to study the pharmacology of the anti-IL-21R antibody ATR-107 in human whole blood , 2013, Journal of Translational Medicine.

[22]  Leonid Gibiansky,et al.  Approximations of the target-mediated drug disposition model and identifiability of model parameters , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[23]  P. Hartig,et al.  Target site occupancy: emerging generalizations from clinical and preclinical studies. , 2009, Pharmacology & therapeutics.

[24]  B. Meibohm,et al.  Population Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.